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Abstract
Cellular and viral microRNAs (miRNAs) are involved in many different processes of key importance and more than 10,000
miRNAs have been identified so far. In general, relatively little is known about their biological functions in mammalian cells
because their phenotypic effects are often mild and many of their targets still await identification. The recent discovery that
Epstein-Barr virus (EBV) and other herpesviruses produce their own, barely conserved sets of miRNAs suggests that these
viruses usurp the host RNA silencing machinery to their advantage in contrast to the antiviral roles of RNA silencing in plants
and insects. We have systematically introduced mutations in EBV’s precursor miRNA transcripts to prevent their subsequent
processing into mature viral miRNAs. Phenotypic analyses of these mutant derivatives of EBV revealed that the viral miRNAs
of the BHRF1 locus inhibit apoptosis and favor cell cycle progression and proliferation during the early phase of infected
human primary B cells. Our findings also indicate that EBV’s miRNAs are not needed to control the exit from latency. The
phenotypes of viral miRNAs uncovered by this genetic analysis indicate that they contribute to EBV-associated cellular
transformation rather than regulate viral genes of EBV’s lytic phase.
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Introduction
Thousands of microRNAs (miRNAs) have been identified so far
(miRBase, release 14, Sept. 2009; http://www.mirbase.org), which
are small noncoding single-stranded RNAs of about 21 to 25
nucleotides in length. They are found transcribed in all multicellular
organisms and certain viruses and often are phylogenetically
conserved across species [1–3]. The 59-ends of miRNAs, the so-
called seed sequences, recognize partially complementary mRNA
targets usually within their 39 untranslated regions and repress
translational of these mRNAs [4]. In recent years, miRNAs have
emerged as key regulators of a number of biological processes
including developmental timing, differentiation and pattering, but
also cellular proliferation, cell death, immune response, haemato-
poesis, and cellular transformation or oncogenesis [5–10]. Individ-
ual miRNAs can directly regulate the expression of hundreds of
different mRNAs [11] and possibly influence the steady state levels
of more than 30% of the proteins in mammalian cells [2,12].
One standard approach to identify targets of miRNAs relies on
computational algorithms that build on thethermodynamicstability
of miRNA/mRNA complexes and the evolutionary conservation of
miRNA seed sequences [13] because sequences of the (cellular)
mRNA target molecules are frequently preserved across species
[10]. One major disadvantage of this dual approach lies in a large
number of false positive predictions because many putative mRNA
target sites might not be accessible due to mRNA folding. In
addition, as this computational approach eliminates potential
targets that are not conserved between different species or related
viruses, itis inadequateforpredicting targets of herpesviralmiRNAs
because their evolutionary conservation is surprisingly low among
members of the herpesvirus family [14–16].
An alternative approach uses microarray analyses of cellular
mRNAs upon ectopic expression of individual or multiple
miRNAs [5,17,18]. This approach is useful to reveal direct and
indirect downstream targets of miRNAs but it may miss authentic
targets if their mRNA levels are not sufficiently down-regulated for
reliable detection by microarray analysis. In addition, antisense
oligonucleotides [19,20] or competitive inhibitors [21] have been
used for the experimental identification and/or subsequent
verifications of potential target genes.
The identification and functional assessment of miRNAs can
reveal a rich biology. One prominent example is the human miR-
155, the product of the bic gene [22]. miR-155 was found to be
overexpressed in several types of B-cell lymphoma [23] and its
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miR-155 is an orthologue of Kaposi sarcoma-associated herpes-
virus (KSHV)-encoded miR-K12-11 [25,26] and candidate target
genes, identified by microarray analysis, were confirmed to be
regulated similarly by miR-K12-11 [ibid and 17]. Beyond this
prominent example, relatively few targets of viral miRNAs have
been experimentally confirmed probably due to a large number of
false positive predictions and poor evolutionary conservation of
viral miRNAs [14].
We have generated recombinant EBVs modified in their
capacity to encode EBV’s miRNAs to probe their functions in
the viral life cycle. We show that viral mutants deficient in
BHRF1 miRNAs are dramatically reduced in their support of
proliferation of infected B cells early after infection. B cell
newly infected with EBV lacking the BHRF1 miRNAs
progressed through the cell cycle less efficiently and died by
apoptosis more often than cells infected identically with the
parental EBV. Our phenotypic characterization revealed that
EBV’s miRNAs support EBV-mediated B-cell activation but
play no apparent role in maintaining viral latency in contrast
to the miRNAs of Kaposi’s sarcoma-associated herpesvirus
(KSHV) [27 and references therin] showing that the miRNAs of
related human c-herpesviruses evolved to perform divergent sets
of functions.
Results
Functional deletion and reconstitution of viral miRNAs in
B95.8-based mutant EBVs
We assessed the role of EBV’s miRNAs in EBV-mediated B-
cell activation, transformation and/or viral latency genetically.
All EBV’s miRNAs are clustered in two areas of the genome, the
BHRF1 and BART genes. We generated two recombinant EBV
mutants that carry inactivated alleles of the BHRF1 or BART
miRNAs or both (Figure 1) on the basis of the E.coli-cloned
genome of the B95.8 strain of EBV [28]. This EBV genome,
designated 2089 and regarded as the recombinant version of
prototypic EBV [29], encodes three BHRF1 and five BART
pre-miRNAs, which are processed to four BHRF1 and nine
BART mature miRNAs, respectively (Figure 1B). To replace the
wild-type alleles by nonfunctional alleles of the viral miRNAs, we
altered all eight pre-miRNAs from which the 13 mature miRNAs
sequences of this EBV strain arise to computed, scrambled
versions that are expected to interfere with Drosha processing
(Table 1 and Supporting Figure S1). All EBV miRNAs are
located in non-coding regions of the BHRF1 and BART
transcripts and genetic modifications within these sequences are
therefore not expected to affect the protein coding capacities of
both genes. The scrambled primary RNA sequences were
designed to maintain the wild-type nucleotide composition and
the overall genomic architecture of the original EBV DNA but to
be unable to fold into the specific hairpin structures of pri-
miRNAs. As a consequence the nuclear RNaseIII enzyme
Drosha would not process the scrambled RNAs and no mature
functional miRNAs could form. We replaced EBV’s pre-miRNAs
with their scrambled mutant sequences (Figure 1B and Support-
ing Figure S1) using galK-mediated recombination [30] in four
consecutive rounds of genetic manipulation in E. coli (see Material
and Methods for experimental details). The two final EBV
mutants were checked by detailed restriction enzyme analyses.
DNA sequencing confirmed the intended genetic alterations of
the viral pre-miRNAs and the integrity of the maxi-EBV
genomes. DmirBHRF1 EBV lacks the coding capacity of the
BHRF1 miRNA locus and DmirALL EBV is devoid of all viral
miRNAs (Figure 1B). Both mutant EBVs are otherwise prototype
2089 without any further genetic alterations, additional marker
genes, or their remnants.
As shown in Figure 1A, EBV field strains other than the
reference strain B95.8 encode up to 25 pre-miRNAs, which result
in four mature BHRF1 miRNAs and 40 BART miRNAs. To
examine the role of BART miRNAs that are not encoded in
B95.8, we generated the reconstituted EBV mutant that
ectopically expresses the full set of all BART miRNAs
(+mirBART in Figure 1C). To construct this mutant, the BART
miRNA cluster with twenty-two pre-miRNAs was assembled
from sub- genomic fragments of the three distinct loci within the
BART region (Figure 1A). The loci were PCR-amplified from
Jijoye cell DNA and cloned into the expression vector pCDNA3.
PCR primers were designed such that DNA stretches of at least
150bp in length flank each of the miRNA loci. Hence, all pre-
miRNAs remain in their authentic sequence context minimizing
the risk of aberrant RNA folding. This expression cassette was
introduced into the BALF1 gene of prototype 2089 EBV
(Figure 1C) as described in detail in the Material and Methods
section. BALF1 encodes a viral homologue of the Bcl-2 family,
and the insertion obliterates its coding capacity but BALF1 is a
redundant gene and therefore dispensable for EBV’s transform-
ing functions [31].
Stocks of mutant viruses were generated in HEK293 cells
stably transfected with maxi-EBV plasmid DNAs purified from
E. coli [28]. Virus was produced after lytic cycle induction of the
resulting HEK293 producer cell clones and quantified by
infecting the B cell Raji cell line as described [32]. Because
our recombinant EBVs encode green fluorescence protein (gfp),
we could measure the concentration of GFP-transducing virions
as ‘‘green Raji units’’ (GRU). We obtained virus stocks in the
range of 10
4–10
5/ml GRUs similar to prototype 2089 EBV
stocks [28].
We prepared primary human B cells from three samples of
adenoid tissue and two samples of peripheral blood and infected
them as described in detail in Material and Methods with
prototype 2089 EBV or one of the three miRNA mutant EBVs.
We obtained five sets of lymphoblastoid cell lines (LCLs), 20 in
Author Summary
Micro RNAs (miRNAs) are small, non-coding RNAs that bind
to mRNA transcripts and abrogate their protein coding
functions. Only a few of their mRNA targets are known,
although miRNAs are found in all multicellular organisms
and certain viruses. In particular, members of the
herpesvirus family encode a surprisingly large number of
miRNAs. Epstein-Barr virus (EBV) belongs to this virus
family and is associated with several human malignancies
including B-cell lymphomas. In vitro, this virus infects
human primary B cells and transforms them into contin-
uously proliferating lymphoblastoid cell lines (LCL), which
is an amenable model covering key aspects of cellular
transformation and lymphomagenesis. To assess the roles
of EBV’s miRNAs in this model, we generated EBV mutants
that lack the capacity to encode viral miRNAs. Phenotypic
analysis of human primary B cells infected with these
mutant viruses revealed that miRNAs encoded in EBV’s
BHRF1 locus strongly promote B cell proliferation, regulate
cell cycle functions, and prevent apoptosis early after
infection. Our findings show that EBV has evolved discrete
miRNAs to contribute to its well-known transforming
capacity, which has not been appreciated previously.
miRNAs of Epstein-Barr Virus
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(p.i.).
Steady state levels of selected BHRF-1 and BART miRNAs
in established LCLs
We determined the steady state levels of two BHRF1 (Figure 2A,
B) and fiveBART miRNAs (Figure 2C to G)inthe established LCLs
by quantitative real-time stem-loop PCR analyses. As a positive
control,JMLCLwasused,anLCLinfectedwithanuncharacterized
field strain of EBV that expresses all 44 viral miRNAs. The copy
numbers of selected miRNAs per cellular transcriptome were
determined with synthetic miRNA standards as references.
Prototype 2089 EBV-infected LCLs expressed BHRF1 miRNAs
in the range of 8,000–12,000 copies per cell, which exceeded levels
in JM LCL (Figure 2A, B). Expression levels of BHRF1 miRNAs
in +mirBART EBV-infected LCLs were in the same range as in
prototype 2089 EBV-infected LCL. As expected LCLs infected
with DmirBHRF1 and DmiALL EBVs did not express the
functionally deleted miRNAs.
We assessed the expression levels of two BART miRNAs of
prototype 2089 EBV (Figure 2C, D) and three BART miRNAs
absent in this EBV strain (Figure 2E to G). miR-BART1-5p
and miR-BART2-5p were expressed at about 100–500 copies
per cell. The relative low expression of BART miRNAs as
compared to BHRF1 miRNAs is in accordance with the
literature [33 and references therein] and was also observed in
JM LCL cells infected with an uncharacterized field strain of
EBV. LCLs infected with DmirBHRF1 EBV expressed these
BART miRNAs at levels similar to prototype 2089 EBV-
infected LCLs. +mirBART EBV infection mildly increased the
levels of miR-BART1-5p and miR-BART2-5p (Figure 2C, D).
Steady state levels of those miRNAs absent in B95.8-derived
Figure 1. Schematic overview of the construction of miRNA-mutated EBVs. (A) Genomic localization of EBV’s miRNAs in the EBV reference
strain AJ507799. The two miRNA families of EBV originate from two transcripts that fold into 25 pre-miRNAs as indicated by black bars and give rise to
four mature BHRF1 miRNAs and 40 BART miRNAs. (B) Functional ablation of EBV’s miRNAs. Prototype 2089 EBV is based on the prototypic EBV strain
B95.8 [29], which was cloned in E. coli [28]. As compared to the Genbank entry of the hypothetical EBV reference strain AJ507799, the genome of
B95.8 suffers from a deletion and therefore lacks the coding capacity of the majority of the BART miRNAs as indicated. In E. coli, the three pre-miRNA
structures in the BHRF1 locus of prototype 2089 EBV were replaced with computed scrambled sequences (Table 1) to generate a functional BHRF1
miRNA knock-out EBV termed DmirBHRF1 (or p4004). In a subsequent step, the remaining five BART pre-miRNAs were replaced with scrambled
sequences to generate an EBV genome devoid of any miRNAs. This mutant was termed DmirALL (or 4027). The sequence of miR-BART5 is present in
the genome of prototype 2089 EBV but due to the deletion in the parental B95.8 strain the pre-miRNA cannot form the hairpin structure needed for
miR-BART5’s processing by Drosha as indicated (*) in Figure 1B. (C) Construction of a reconstituted EBV mutant encoding 22 BART pre-miRNAs. The
expression cassette p4079, which encodes all pre-miRNAs of the BART locus, was introduced into the BALF1 locus of the prototype 2089 EBV genome
by homologous recombination as indicated. The EBV mutant that carries all BART miRNAs encoded by conventional EBV strains, was termed
+mirBART (or p4080).
doi:10.1371/journal.ppat.1001063.g001
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cells than in JM LCL cells (Figure 2E to G).
EBV’s miRNAs have no discernable role in maintaining
viral latency
Viral miRNAs have been implicated in maintaining herpesviral
latency by inhibiting induction of the lytic cycle [34 for a recent
review]. We therefore asked whether deleting EBV’s miRNAs might
lead to spontaneous induction of EBV’s lytic phase in LCLs. We
analyzed the expression of BZLF1 by semi-quantitative RT-PCR
and theexpressionofBLLF1byFACSinestablishedLCLs.BZLF1is
the molecular switch gene of EBV, which can induce EBV’s lytic
phase, and BLLF1 codes for the late structural glycoprotein gp350/
220 expressed on the surface of productively infected cells. The
expression levels of BZLF1 transcripts did not consistently differ
between B cells infected with prototype 2089 or miRNA mutant
EBVs (Figure 3A). BLLF1 as a late lytic gene was also not detectably
expressed in established LCLs infected with miRNA mutant EBVs
(Figure 3B) indicating that EBV’s miRNAs are not essential for
maintaining herpesviral latency or inhibiting spontaneous reactiva-
tion of EBV’s lytic phase in established cell lines.
We were surprised to learn that obliterating EBV’s miRNAs did
not lead to increased lytic reactivation given that other herpesvirus
such as KSHV, HSV, and CMV have been reported to encode
miRNAs, which maintain and stabilize latent infection [35–39].
We therefore analyzed the expression of BZLF1 mRNAs by
semiquanitative RT-PCR in primary B cells from three different
donors infected with the different mutant EBVs five and 15 days
p.i.. Again, no discernable differences were seen indicating that
BZLF1 transcripts are not regulated by EBV’s miRNAs
(Figure 3C). At early time points post infection BZLF1 is expressed
at relative high levels [40,41] but nevertheless cannot induce
EBV’s lytic phase [41]. Our recent findings together suggest that
in contrast to other members of the herpesvirus family [34] EBV
does not rely on its miRNAs but uses alternative means to control
establishment or maintenance of latency.
Functional deletion of BHRF1 miRNAs causes minor
alterations in cell cycle distribution but does not affect
survival of established LCLs
While cultivating the twenty LCL lines for up to five months p.i.
we noticed that LCLs infected with DmirBHRF1 and DmirALL
proliferated slightly slower than LCLs infected with prototype
2089 or +mirBART EBVs (data not shown). We therefore
analyzed the phenotypes of viral miRNA EBV mutants in
established LCLs by monitoring their cell cycle distribution and
the fraction of apoptotic cells.
The 20 LCL lines were plated at initial cell densities of 10
5 cells
per ml and cultured for 2 days. Surface staining for Annexin-V,
uptake of propidium iodine (PI), and FACS analyses of their DNA
content after BrdU incorporation revealed the fraction of living
cells and their cell cycle distributions, respectively. The propor-
tions of cells that were double negative for Annexin-V and PI
staining ranged between 75 to 85% for LCLs infected with either
prototype 2089 or miRNA mutant EBVs (Figure 4A) with no
discernable differences. LCLs infected with DmiBHRF1 and
DmirALL mutant EBVs showed a slightly increased proportion of
cells in G0/G1 with a reduction of cells in S phase when compared
to prototype 2089 EBV-infected LCLs (Figure 4B). This tendency
was mostly statistically significant (Supporting Figure S2) and
suggested a possible role of EBV’s BHRF1 miRNAs in controlling
proliferation in latently infected cells.
A previous, detailed genetic analysis of the BHRF1 gene, a viral
homologue of the cellular Bcl-2 family, had not revealed a
measurable phenotype in latently infected primary human B cells
[31]. BHRF1 is a redundant gene because EBV carries two alleles
of Bcl-2 family members, BHRF1 and BALF1, which are both
highly expressed shortly after infection. Singly inactivated BALF1
2
or BHRF1
2 mutant EBVs were capable of yielding clonal LCLs
but at a slightly higher dose than wild-type EBV. Only viral
mutants with two inactivated Bcl-2 genes (i.e. both BALF1 and
BHRF1) failed to rescue infected primary B lymphocytes from
spontaneous apoptosis, prevented their cell cycle entry and did not
Table 1. Wild-type sequences and corresponding scrambled versions of EBV-encoded miRNAs.
miRNA Wild-type sequence (59 to 39) Scrambled sequence (59 to 39)
miR-BHRF1-1 UAACCUGAUCAGCCCCGGAGUU GAUAAUAACCCGGGUGCCCCUU
miR-BHRF1-2-5p* AAAUUCUGUUGCAGCAGAUAGC CGGUAGGUGAUAUCCAAACUAU
miR-BHRF1-2-3p UAUCUUUUGCGGCAGAAAUUGA GAAACUUCUGGAUCGUGAUUAU
miR-BHRF1-3 UAACGGGAAGUGUGUAAGCACA UGAAGAUAAGGUCCACGGAAUG
miR-BART3-5p* ACCUAGUGUUAGUGUUGUGCU GCCUAGUUUCGGUUGUGUAAU
miR-BART3-3p CGCACCACUAGUCACCAGGUGU UGUGUCCACCACAAACUGCCGG
miR-BART4 GACCUGAUGCUGCUGGUGUGCU CAGAGCCUUUUGGGUCGGUCGU
miR-BART4* CACAUCACGUAGGCACCAGGUGU
#)
miR-BART1-5p UCUUAGUGGAAGUGACGUGCUGUG UGGGACCUUAUGGUAUGUGGAUCG
miR-BART1-3p UAGCACCGCUAUCCACUAUGUC CAAUUAGAUUCACCCUCCCUGG
miR-BART15 GUCAGUGGUUUUGUUUCCUUGA UCGCUUUGUUUUGUUGUGACAG
miR-BART5
+) CAAGGUGAAUAUAGCUGCCCAUCG UUCAAUCAACGGAGUCGAAGUCCG
miR-BART2-5p UAUUUUCUGCAUUCGCCCUUGC CGAACUUCUUUCCGUGUUUUCC
miR-BART2-3p AAGGAGCGAUUUGGAGAAAAUAAA AAGAUGAAAAUCGAUUAGGGGAAA
#) The sequence of miR-BART4* is present in all 2089-derived mutant EBVs but its pre-miRNA cannot form the necessary stem of the hairpin structure in DmirALL
because the sequence of the 59 arm is scrambled as in miR-BART4.
+) The sequence of miR-BART5 is present in prototype 2089 EBV but due to the deletion in the parental B95.8 EBV strain it cannot fold into the pre-miRNA hairpin
structure and is therefore not processed to the mature miR-BART5 even in the prototype 2089 EBV and B95.8 strains.
doi:10.1371/journal.ppat.1001063.t001
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for growth transformation by EBV because the two viral vBcl-2
members encode similar functions.
A recent publication indicated that BHRF1 is constitutively
expressed as a latent protein in growth-transformed cells in vitro
and may contribute to virus-associated lymphomagenesis in vivo
[42]. Therefore, we were concerned that our current findings
might result from reduced steady-state transcript levels of BHRF1
mRNA, which could be the consequence of the altered pre-
miRNA sequences located in the 59 and 39 untranslated regions of
that mRNA (Figure 1A). The alterations could adversely affect
mRNA translation and reduce BHRF1 protein levels. Because
antibodies that unambiguously detect BHRF1 protein early after
infection or in strictly latently infected LCLs are not available, we
assessed BHRF1 mRNA levels by quantitative RT-PCR analyses
in established LCLs or primary B cells infected with prototype
2089 EBV or DmirBHRF1 mutant EBVs for five days, only
(Supporting Figure S3). No discernable differences in LCLs were
observed (Supporting Figure S3A and data not shown) but
primary B cells infected with DmirBHRF1 revealed slightly
enhanced (up to twofold) levels of BHRF1 mRNA early after
infection (Supporting Figure S3B and data not shown). Our
Figure 3. Expression of BZLF1 and BLLF1 in prototype 2089 or miRNA mutant EBV-infected LCLs. (A) Semi-quantitative RT-PCRs of
transcripts of the immediate-early gene BZLF1 in established LCLs from five different donors (D1 to D5) infected with prototype 2089 EBV (wt) or the
indicated miRNA mutants. cDNAs prepared from B95.8 and Raji cells served as positive and negative controls, respectively. The levels of cytochrome c
mRNA were used as loading controls. (B) FACS analysis of the surface expression of gp350/220 encoded by the late EBV gene BLLF1. LCLs were
stained with a mouse anti-gp350 monoclonal antibody, followed by APC-conjugated goat anti-mouse IgG antibody (black histograms). The gray
histograms represent the staining of the secondary antibody, only. A 7.2% fraction of B95.8 cells spontaneously supports EBV’s lytic phase. One
representative set of LCLs from one out of five different donors is shown. (C) Semi-quantitative RT-PCR analysis of BZLF1 transcripts in primary B cells
at day 5 and 15 p.i. infected with prototype 2089 EBV (wt) or the indicated miRNA mutant EBVs. Primary human B cells isolated from adenoids were
infected at a concentration of 4.5610
5 per ml with an MOI of 0.2.
doi:10.1371/journal.ppat.1001063.g003
Figure 2. Absolute quantification of EBV-encoded miRNAs in established LCLs infected with prototype 2089 or miRNA-mutant
EBVs. Steady-state levels of two BHRF1 miRNAs (panels A, B) and five BART miRNAs (panels C to G) in prototype 2089 or miRNA-mutant EBV-infected
LCLs from two different donors were determined by quantitative stem-loop PCR assays. Two BART miRNAs present in the wild-type reference strain
B95.8 (panels C, D) and three BART miRNAs deleted in B95.8 but present in +mirBART EBV (panels E to G) were subjected to quantification. JM LCL is a
spontaneous LCL infected with an uncharacterized field strain of EBV encoding 44 viral miRNAs. The numbers of miRNA molecules per cell were
determined and calculated with standards generated with RNA of DmirALL EBV-infected LCLs doped with serial dilutions of synthetic miRNAs. The
reconstructions were based on quantification of total RNA harvested from a known number of cells of the different LCLs prior to quantitative stem-
loop PCRs. Results are shown as absolute miRNA molecules per RNA mass obtained from a single cell. Data represent the means and standard
deviations of three independent quantifications. Prototype 2089 EBV-infected cells are indicated (wt).
doi:10.1371/journal.ppat.1001063.g002
miRNAs of Epstein-Barr Virus
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primary B cells failed (data not shown). Low protein expression
levels or the insufficient sensitivity of available antibodies prevent
the detection of BHRF1 at early time points after infection but our
quantitative RT-PCR results indicated that scrambling of the
untranslated BHRF1 pre-miRNA sequences upstream and
downstream of the BHRF1 coding sequence did not negatively
affect the expression levels of this transcript. On the contrary the
genetic alterations might even improve the expression or stability
of the BHRF1 transcripts up to twofold (Supporting Figure S3B),
which is expected to result in mildly enhanced protein levels that
should counteract apoptosis in latently and newly infected primary
B cells [31,42 and references therein].
Functional deletion of BHRF1 miRNAs reduces early B-cell
proliferation
Our studies with established LCLs infected with BHRF1
miRNA mutant EBVs indicated that these cells differed only in
their cell cycle distribution but lacked other obvious phenotypes.
We have found that the very early but transient expression of
several lytic viral genes in primary human B cells is critical for their
subsequent transformation and stable latent infection [31,41].
BHRF1 is among the genes that are massively expressed initially
after infection [31,42]. It codes not only for one of the two viral
Bcl-2 homologous but also for three pre-miRNAs that give rise to
the four mature miRNAs of the BHRF1 locus (Figure 1A) [33 and
references therein]. We suspected that the strong, initial expression
of this gene might have implications for the expression and
function of the encoded miRNAs and therefore examined their
expression and the proliferation of primary B cells infected with
prototype 2089 EBV or miRNA mutant EBVs at early time points
post infection.
First, primary B cells prepared from adenoids were infected with
prototype 2089 EBVs with a high multiplicity of infection (MOI)
of 0.2 to ensure infection of many primary B cells. Quantitative
stem-loop PCR analyses assessed the absolute levels of two
miRNAs, miR-BHRF1-1 and miR-BHRF1-2-3p at day 5 p.i.. In
primary cells miR-BHRF1-1 and miR-BHRF1-2-3p were ex-
pressed at about four- and twofold higher levels, respectively, early
after infection (Supporting Figure S4; panels A and B) as
compared to established LCLs infected with the same prototype
2089 EBV (Figure 2A, B). The levels early after infection exceeded
the steady state levels of BHRF1 miRNAs seen in the reference JM
LCL infected with an uncharacterized field strain of EBV
(Supporting Figure S4; panels A and B). Similar findings apply
to the expression levels of BART miRNAs early after infection
(Supporting Figure S4), which were in a similar range or even
exceeded those seen in JM LCL cells (miR-BART2-5p, miR-
BART22, miR-BART1-5p; Supporting Figure S4C, D, F) with
one exception (miR-BART8-5p; Supporting Figure S4E).
Next, primary B cells prepared from adenoids were infected
with viral stocks having identical titers of the three different
mutant EBVs, DmirBHRF1, DmirALL, and +mirBART EBV and
prototype 2089 EBV with an multiplicity of infection (MOI) of
0.05 and a concentration of 4.5610
5 cells per ml for 18hours.
After collection and resuspension in fresh medium to the initial
density, the infected cells were cultivated and analyzed by FACS at
5, 9, and 12 days p.i. (Figure 5A). Uninfected primary B cells
showed the typical forward (FSC) and sideward (SSC) scatter
characteristic of small and resting cells. Infected cells acquired
typical lymphoblastic characteristics of activated cells, increased
their forward and sideward scatter and were found in the defined
LCL gate (Figure 5A, top panels). The absolute numbers of cells in
this gate were determined by FACS counting with the aid of added
APC-coupled calibration beads as a volume standard as described
[31]. After infection with the two miR-BHRF1-negative EBVs,
DmirBHRF1 and DmirALL, fewer cells were present in the LCL
gate than after infection with prototype 2089 EBV as early as 5
days p.i. In contrast, the number of cells infected with +mirBART
EBV was in a similar range as prototype 2089 EBV (Figure 5A).
The inactivation of the BHRF1 miRNAs led to a four to five-fold
reduction in outgrowth of B cells from three different donors
(Figure 5B). The reduced numbers of growing cells infected with
DmirBHRF1 or DmirALL EBVs were consistently observed over
Figure 4. Established LCLs infected with BHRF1 miRNA mutant
EBVs show an altered cell cycle distribution but no survival
phenotype. Long-term (three to five months p.i.) cultured cells
infected with either prototype 2089 or miRNA-mutated EBVs were
analyzed for spontaneous apoptosis and cell cycle distribution. (A)
Established LCLs were plated (10
5 per ml) in fresh medium and cultured
for two days. The cells were analyzed by FACS for Annexin-V and PI
staining. The error bars represent the standard deviation of the mean of
cells in this experiment from five different donors. (B) Cell cycle analysis
of established LCLs. Cells were plated (10
5 per ml) in fresh medium and
cultured for two days, then analyzed by standard BrdU incorporation
assays. The error bars represent the standard deviation of the mean of
cells in this experiment from four different donors.
doi:10.1371/journal.ppat.1001063.g004
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PLoS Pathogens | www.plospathogens.org 7 August 2010 | Volume 6 | Issue 8 | e1001063Figure 5. Outgrowth of primary human B cells infected with prototype 2089 or miRNA-mutated EBVs. Primary human B cells of three
donors isolated from adenoids (4.5610
5 per ml) were infected with either prototype 2089 or miRNA-mutated EBVs at an MOI of 0.05. At day 5, 9, and
12 p.i., cells were harvested and their outgrowth analyzed by FACS. To determine the absolute number of cells counted, a volume standard was
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showed a slightly prolonged doubling time, which was not
significantly different (p$0.1, paired t test; data not shown) when
compared to prototype 2089 or +mirBART EBV-infected cells
(about 2 to 2.5 days/cell generation; Figure 5C). These combined
observations showed that BHRF1 miRNAs are critical in primary
B cells early after infection but largely dispensable in established
LCLs.
BHRF1 miRNAs protect primary B cells from spontaneous
apoptosis early after infection
Our initial findings indicated that BHRF1 miRNAs support B
cells early after EBV infection but did not distinguish between
BHRF1 miRNAs9 regulating cell cycle functions or counteracting
the spontaneous apoptosis of primary B cells. To differentiate
between these two roles, we first determined the proportion of
viable cells in miRNA mutant or prototype 2089 EBV-infected B
cells at different time points early after infection. Forward and
sideward scatter analysis of primary B cells immediately after
preparation showed mostly intact cells with a minor fraction of
subcellular debris (Figure 6A, left panel). Uninfected primary B
cells die rapidly in vitro [31], whereas EBV-infected cells become
lymphoblastoid with characteristically increased forward and
sideward scatter (Figure 6A, right panel). We deliberately chose
a low MOI (0.05) in order to detect small changes in the fraction of
infected and surviving B cells. As a consequence the majority of
cells were uninfected, became highly granular or disintegrated in
the course of infection. The gate in Figure 6 was set in order to
include primary and activated, live and apoptotic cells but to
exclude most of the subcellular debris. The cells in this gate were
analyzed for the binding of Annexin-V and uptake of PI as
indicators of early apoptosis and loss of membrane integrity,
respectively.
Measuring the percentage of cells, which were double-negative
for Annexin-V and PI staining indicated that nearly 90% of the
cells were alive on day 0 (Figure 6C). Infection with prototype
2089 EBV yielded up to 70% of cells, which were Annexin-
V- and PI-negative twelve days p.i.. Both EBV mutants,
DmirBHRF1 and DmirALL, also rescued the infected cells from
cell death but considerably less efficiently than prototype 2089
EBV (Figure 6C). As already pointed out, we cannot unambig-
uously dissect BHRF1 protein-mediated effects from BHRF1
miRNA-mediated effects due to a lack of antibody reagents.
However, the genetic and functional redundancy of EBV’s anti-
apoptotic Bcl-2 homologs [31] and the analysis of the levels of the
BHRF1 transcript (Supporting Figure S3) clearly point to
miRNAs of the BHRF1 cluster and their role in inhibiting
apoptosis.
The larger fraction of apoptotic cells infected with the two
mutant EBVs likely contributes to some of the reduction in
numbers of proliferating cells in Figure 5 consistent with BHRF1
miRNAs contributing to cellular proliferation by supporting initial
B-cell survival. We did not observe a clear difference between
prototype 2089 EBV- and +mirBART EBV-infected cells, as
would be expected from their similar growth characteristics
(Figure 5).
BHRF1 miRNAs affect cell cycle distribution of infected B
cells
Cells infected with DmirBHRF1 and DmirALL EBVs showed
slightly prolonged doubling times (Figure 5C). We employed BrdU
incorporation assays to compare the cell cycle distributions of the
differently infected B cells early after infection as accurately as
practical. The cell cycle status of uninfected (day 0) or infected cells
on day 5, 9, and 12 p.i. with characteristics of resting lymphocytes
and activated lymphoblasts in forward/sideward scatter analysis
(Figure 7A) was analyzed by determining BrdU incorporation and
7-AAD uptake by FACS (Figure 7B). On average 7.2% of the
uninfected cells were in S-phase immediately after isolation
(Figure 7C). Whereas uninfected cells died rapidly, 39% or 35%
of prototype 2089 or +mirBART EBV-infected cells were in S
phase five days p.i.. In contrast, DmirBHRF1 and DmirALL EBV-
infected cell cultures contained fewer cells in S-phase (21% or
17%, respectively) consistent with an increase in cells in G0/G1
and a higher proportion of apoptotic cells (Figure 7C). Thus, it
appears that BHRF1 miRNAs both promote cell cycle entry or
progression and block apoptosis in B cells early after their
infection.
Discussion
EBV is now thought to encode more miRNAs than do other
herpesviruses yet little has been established about the roles of these
regulatory genes in EBV’s life cycle. We have used genetic analysis
to identify phenotypes mediated by the BHRF1 cluster of miRNAs.
Derivatives of EBV lacking these miRNA genes yielded established
B cell lines that behaved as did those infected with wild-type virus.
However, careful scruting of B cells immediately following
infection has uncovered two complementary functions that the
BHRF1 miRNAs provided these cells. By five days post infection
twice the numbers of cells infected with EBV lacking the BHRF1
miRNAs were undergoing apoptotic death as were those infected
with EBV encoding these miRNAs. At this same time twice as
many viable cells infected with EBV encoding the BHRF1
miRNAs were in S phase as were those infected with EBV lacking
these miRNA genes. These findings indicate that the BHRF1
miRNAs inhibit apoptosis and promote proliferation during the
early stages of infection. They are thus acting at a stage in the life
cycle when EBV’s multiple oncogenes are only beginning to
function. The EBV-mediated differentiation of the resting B cell to
the proliferating B cell blast requires multiple days following
infection at low multiplicity, a scenario likely to reflect infections in
vivo. It is under these circumstances that the BHRF1 miRNAs
contribute substantially to promoting survival and proliferation of
the infected B cell.
The functions of EBV’s BHRF1 miRNAs differ from those
characterized in KSHV’s genome. In KSHV, an EBV-related
human herpesvirus, several miRNAs counteract the spontaneous
onset of KSHV’s lytic cycle. Their expression promotes or
maintains viral latency and shuts off viral lytic proteins. For
example, two groups recently demonstrated that two different
miRNAs of KSHV, miRK9* and miRK5, can down-regulate the
expression of the viral transcription activator RTA [27,35].
added prior to FACS analysis as described [31]. (A) Representative results of FACS analysis. EBV-infected cells with elevated forward (FSC) and
sideward (SSC) scatter characteristics indicative of activated lymphoblast cells were gated as indicated and the number of cells in this gate was
recorded. (B) The ratios of the numbers of lymphoblastic cells infected with single miRNA mutant EBVs versus prototype 2089 EBV-infected cells were
calculated. Functional deletion of EBV-encoded BHRF1 miRNAs led to substantially lower numbers of outgrowing lymphoblasts compared to wild-
type EBV-infected cells. The error bars represent the standard deviation of the mean of cells from three different donors. (C) Doubling times of
primary B cells infected with either prototype 2089 or miRNA-mutated EBVs calculated from the results in (B).
doi:10.1371/journal.ppat.1001063.g005
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PLoS Pathogens | www.plospathogens.org 9 August 2010 | Volume 6 | Issue 8 | e1001063Figure 6. Spontaneous apoptosis of primary B cells infected with prototype or miRNA-mutated EBVs. To examine the spontaneous
apoptosis of primary B cells early after infection, the samples as shown in Figure 5 were analyzed by FACS for Annexin-V binding and propidium
iodide (PI) staining at different time points p.i.. (A) FSC and SSC characteristics of uninfected and prototype 2089 EBV-infected primary B cells on day 0
and day 5 p.i., respectively. To exclude subcellular debris but include highly granular, presumably dying or dead cells, only cells within the indicated
gate were analyzed for their Annexin-V and PI staining. (B) Annexin V/PI staining analysis of B cells infected with 2089 EBV or miRNA mutants at
different time points p.i.. One representative experiment out of three is shown. Cells in the AnnexinV
2/PI
2 quadrants (red boxes) indicate surviving
cells at each time point p.i.. (C) Summary of the data shown in (B). The proportion of live, AnnexinV
2/PI
2 cells at each time point p.i. was calculated.
Fewer live cells were detected after DmirBHRF1 or DmirALL EBV infection than after prototype 2089 or +mirBART EBV infection indicating an anti-
apoptotic role of the BHRF1 miRNAs during the early phase of B cell infection. The error bars represent the standard deviation of the mean of three
different experiments.
doi:10.1371/journal.ppat.1001063.g006
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IkBa protein level to increase NF-kB activity and indirectly inhibit
viral lytic replication in certain cells [36]. It is tempting to
speculate that the role of KSHV’s miRNAs is not only to maintain
latency but also to prevent the spontaneous expression of viral lytic
genes, which, by analogy with EBV, might otherwise increase the
susceptibility of virus-infected cells to T effector cells. Similar
results have been obtained while studying the functions of
miRNAs encoded in CMV and HSV, which also help maintain
latent infection [38,39].
A subset of BART miRNAs can negatively regulate the viral
oncoprotein LMP1 (latent membrane protein 1) in nasopharyn-
geal carcinoma cells [43]. LMP1 has transforming activity but its
high expression can cause growth inhibition and apoptosis. LMP1
regulates its level through its regulation of the Unfolded Protein
Response (UPR) pathway and autophagy. EBV’s miRNAs might
limit inappropriately high LMP1 levels and thereby prevent
apoptosis resulting from LMP1’s regulation of the UPR [44–46]. It
has also been shown that the pro-apoptotic protein PUMA (p53-
upregulated modulator of apoptosis) is a target of miR-BART5
when expressed in epithelial cells, which prototype 2089 EBV does
not encode (Figure 1). We investigated the expression levels of
LMP1 and PUMA in 20 LCLs infected with prototype 2089 or
miRNA mutant EBVs but did not observe a consistent correlation
with the expression levels of LMP1 protein or PUMA mRNA
(data not shown). The relative low expression levels of the BART
miRNAs in the reconstituted EBV mutant +mirBART in
established LCLs might not be sufficient to reveal phenotypes
that correlate with the regulation of the two proteins in B cells with
a latency III type program (Figure 2C–G). The low steady state
levels might also mask other phenotypes that might be connected
to viral reactivation or additional phenotypic effects not diclosed in
this work. This caveat is of concern because the BART miRNAs
are expressed at considerably higher levels in nasopharyngeal
carcinoma cells [47]. Early after infection, these BART miRNAs
(as well as BHRF1 miRNAs) are expressed at much higher levels
(Supporting Figure S4). In fact, we observed under conditions of
low cell density and reduced multiplicity of infection that the
ectopically expressed BART miRNAs of EBV do promote
proliferation of primary human B cells early after infection
(Vereide et al., manuscript submitted).
It is likely that many targets of viral miRNAs remain to be
identified because single miRNAs can target multiple mRNAs
[11]. Computer algorithms based on the conservation of seed
sequences between different species have been successfully used for
the target prediction of cellular miRNAs, but this approach is
hampered for the prediction of the targets of herpesviral miRNAs
because they are evolutionarily poorly conserved [14] and do not
share extended seed homology with cellular transcripts [9 and
references therein]. Conversely, multiple miRNAs could simulta-
neously downregulate a single target gene even if the individual
miRNAs are expressed at relatively low levels [48]. Therefore, the
common experimental approach based on the ectopic expression
or repression of individual miRNAs coupled to subsequent
microarray analysis may prove inadequate to identify targets for
herpesviral miRNAs. Given these difficulties it is essential to
identify phenotypes mediated by EBV’s miRNAs when they are
expressed at physiological levels under normal conditions of
infection as we have done. It is particularly intriguing that these
genetic analyses show that EBV has evolved miRNAs to support
its defining phenotype of transforming infected B cells.
Materials and Methods
Construction of miRNA mutant EBVs
EBVs used in this study were derived from p2089, which
comprises the B95.8 EBV genome cloned onto an F-factor plasmid
in E. coli [28]. The B95.8 EBV strain as well as p2089 encode a
total of 13 known miRNAs, which are located in four clusters
(Figure 1; miR-BHRF1-1, miR-BHRF1-2/3, miR-BART3/4/1/
15/5, and miR-BART2). For their functional ablations, the wild-
type miRNA sequences in each of the four clusters were replaced
with computed, scrambled miRNA sequence (Table 1) in four
consecutive rounds of homologous recombination with the galK-
based recombineering system [30]. In a two-step approach this
system allows modifying the p2089 genome via homologous
recombinations in E. coli without permanently introducing
selectable marker genes or cis-acting sequences (or their remnants)
at the sites of genetic alterations.
Briefly, the recombineering E. coli strain SW105 has a deletion
of the galactokinase (galK) gene and carries a lysogenic and
temperature-sensitive l prophage that makes recombination
amenable. We introduced the p2089 plasmid into SW105 by
electroporation.
In the first targeting step, we wanted to replace the miR-
BHRF1-2/3 miRNAs in p2089 with their scrambled counterparts
shown in Table 1. In the first step we inserted the galK gene into
the miR-BHRF1-2/3 cluster deleting the entire locus. To achieve
this step, the galK targeting cassette was PCR amplified with the
pgalK plasmid as a template [30] with the following conditions:
94uC for 3min for initial denaturation, 94uC for 45sec, 54uC for
45sec, and 72uC for 2.5min in 15 cycles, followed by 20 cycles at
94uC for 45sec, 62uC for 45sec, and 72uC for 2.5min, and a final
elongation step at 72uC for 3min. The PCR primers suitable for
replacing each of the miRNA cluster with galK are listed in
Supporting Table S1. After DpnI digestion, the gel-purified PCR
fragment was electroporated into the heat-induced and therefore
recombination-competent E. coli SW105 strain carrying the
plasmid p2089. After selection for galK on minimal medium plates
with galactose as the sole carbon source, plasmid DNAs were
prepared from galK positive bacterial clones and carefully analyzed
by restriction enzyme analysis. The resulting EBV plasmid p3994
was confirmed to carry galK replacing the BHRF1-2/3 miRNA
cluster.
Figure 7. Cell cycle distribution of primary human B cells infected with miRNA-mutant or prototype 2089 EBVs. Primary B cells
(4.5610
5 per ml) were infected with an MOI of 0.05 of each virus stock as indicated or left uninfected. BrdU incorporation, 7-AAD counterstaining and
FACS analysis determined the cell cycle profiles of cells with characteristics of resting lymphocytes and activated lymphoblasts. (A) FSC and SSC
distribution characteristics of uninfected and prototype 2089 EBV-infected primary B cells on day 0 and day 5 p.i.. To exclude subcellular debris and
highly granular, presumably dying or dead cells, only cells within the indicated gate were analyzed. (B) FACS analysis for their BrdU and 7-AAD
staining. One representative experiment out of three is shown. Gates used to define cells in G1/G0, S and G2/M are indicated. (C) The compiled data
(mean values and standard deviations) of three experiments as exemplified in panel B indicate the different cell cycle profiles of infected B cells at
three time points p.i.. Cells infected with DmirBHRF1 or DmirALL EBV mutants showed an increased fraction of cells in G0/G1 and a concomitant
decrease of cells in S as compared to cells infected with prototype 2089 EBV or +mirBART mutant EBV. Likewise, more cells were found in the subG1
fraction when the cultures were infected with DmirBHRF1 or DmirALL EBV mutants. The differences in cell cycle distributions were most obvious early
after infection on day 5 and diminished thereafter.
doi:10.1371/journal.ppat.1001063.g007
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scrambled DNA sequences that maintain the original nucleotide
composition but ablate the original pre-miRNA structures. The
targeting constructs consisted of the scrambled pre-miRNA
sequence as the core flanked by 150–200 bp long homologous
arms on both sides for the efficient and precise replacement of
galK. The targeting constructs were custom-made, synthetic DNA
fragments cloned into pUC57 and obtained from a commercial
service provider (Genscript Corporation). Four targeting con-
structs were ordered. To replace the galK gene inserted into the
mir-BHRF1-2/3 locus the targeting p3969 plasmid was cut with
appropriate restriction enzymes to liberate the synthetic DNA
fragment. It was gel-purified and electroporated into recombina-
tion-competent E. coli SW105 cells carrying p3994, which were
selected for loss of galK by growth on minimal plates containing 2-
deoxy-galactose (DOG) and glycerol as carbon sources as
described in detail [30]. Plasmid DNAs were prepared from galK
negative bacterial clones and carefully analyzed by restriction
enzyme analysis and extensive DNA sequencing covering at least
two kbps of upstream and downstream flanking sequences in order
to verify the correct insertion of the scrambled miRNA sequences.
We repeated the two-step approach and replaced the miR-
BHRF1-1 cluster with scrambled sequences to generate the
genomic EBV plasmid p4004, which lacks the four miRNAs of
the BHRF1 locus. With this genomic EBV plasmid DmirBHRF1
EBV stocks were established and calibrated as described in detail
[32].
On the basis of p4004, the two BART miRNA clusters in the
cloned genome of B95.8 EBV were further replaced with the
scrambled sequences shown in Table 1. The resulting genomic
EBV plasmid p4027 lacks all functional viral miRNAs (DmirALL
EBV). Restriction enzyme analysis and partial DNA sequencing as
exemplified above verified the genetic compositions of the
modified EBV genomes.
The B95.8 EBV strain and the derived genomic EBV plasmid
p2089 encompass only 13 out of 44 miRNAs as compared to EBV
field strains, which encode 31 additional BART miRNAs. To
reconstitute an EBV genome that has the miRNA coding capacity
of EBV field strains, we introduced an expression cassette, termed
pCMV-miRBART, encompassing all known 22 BART pre-
miRNAs driven by human CMV promoter into the BALF1 locus
of p2089 by homologous recombination (Figure 1C). An
expression cassette was assembled from three sub-genomic
fragments containing the BART miRNAs that map to three
distinct loci within the BART region (Figure 1A). These loci were
PCR amplified from Jijoye cellular DNA and inserted into the
expression vector pCDNA3 (Invitrogen), followed by sequencing
to ensure accurate DNA amplification. Primers were designed
such that DNA stretches of at least 150bp in length flank each of
the miRNA loci. The expression cassette was termed pCMV-
miRBART. The nucleotide positions of the amplified regions were
as follows (all positions are given in reference to GenBank entry
AJ507799): nucleotide coordinates #138803 to #140353 (con-
taining miRs BART1, 23t o26, 215 to 217), nucleotide
coordinates #145331 to #149070 (miRs BART7 to 214, 212 to
214, 218 to 222) and nucleotide coordinates #152509 to
#153034 (miR-BART2). In order to ensure proper function of the
construct, we verified the expression of representative miRNAs
from each of the inserted loci in transiently pCMV-miRBART-
transfected cells by northern blot hybridization confirming similar
relative expression levels as in wild-type EBV infected B-cell lines
(data not shown).
To construct the maxi-EBV genome p4080 (+mirBART in
Figure 1) a tetracycline resistance gene was introduced into the
NruI site of pCMV-miRBART (p3971) to yield p4016. The final
targeting plasmid p4079 was generated by inserting the SspI/DrdI
fragment from p4016 cloned into the SmaI site of p2642, which
contains the BALF1 gene to support its targeted homologous
integration into the BALF1 locus as shown in Figure 1C. The
targeting construct p4079 was linearized with BsrDI/BssHII
digestion and electroporated into the SW105 strain carrying
p2089. After tetracycline selection and restriction enzyme analysis,
DNA sequencing confirmed the genomic EBV plasmid p4080 to
contain the entire targeting construct at the desired location in the
BALF1 locus.
Cells and culture
The EBV-positive Burkitt’s lymphoma cell line Raji, the EBV-
positive marmoset cell line B95.8, and HEK293 cells were
maintained in RPMI 1640 medium (GIBCO). All media were
supplemented with 10% FBS (PAA laboratories), penicillin
(100 U/ml), and streptomycin (100mg/ml). Cells were cultivated
at 37uC in a 5% CO2 incubator.
Preparation and quantification of infectious viral stocks
On the basis of HEK293 cells, virus producer cell lines were
established after individual transfection of the genomic EBV
plasmid DNAs and subsequent selection with hygromycin (80mg/
ml). To obtain virus stocks, the producer cell lines were transiently
transfected with expression plasmids encoding BZLF1 [49], BALF4
[50], and BRLF1 [51] to induce EBV’s lytic cycle. Three days post
transfection, supernatants were harvested and centrifuged at
3000rpm for 15min to remove cell debris. The titers of the
different virus stocks were quantified and the concentrations of
GFP-transducing virions expressed as ‘‘green Raji units’’ (GRUs)
were determined as described previously [31]. Briefly, 10
5 Raji
cells were incubated with serial dilutions of virus stocks at 37uC for
24hours. After an additional culture for 2 days, the percentage of
GFP positive cells was determined by FACS using a FACS-
Calibur instrument (Becton Dickinson).
Isolation, separation, and infection of human primary B
lymphocytes
Human primary B cells from adenoids were separated from T
cells by rosetting with sheep erythrocytes and purified by Ficoll-
Hypaque density gradient centrifugation. B cells isolated from
human peripheral blood mononuclear cells (PBMC) by Ficoll-
Hypaque gradient centrifugation were purified using the B-cell
isolation kit II (Miltenyi Biotec) and MACS separators (Miltenyi
Biotec). For virus infection, primary B cells were incubated with
each virus stock for 18 hrs. After replacement with fresh medium,
the infected cells were seeded at an initial density of 4.5610
5 cells
per ml.
Anonymized adenoid tissue samples from routine adenoidecto-
mies were provided by the Department of Otorhinolaryngology,
Klinikum Grosshadern, Ludwig-Maximilians-University of Mu-
nich. The institutional review board, Ethikkommission of the
Klinikum Grosshadern, approved of the study and did not require
prior informed patient consent.
Analysis of cell proliferation, spontaneous apoptosis and
cell cycle distribution of infected primary B cells
For each time point p.i., 1ml of each cell sample was collected
by centrifugation and stained with 2ml of AnnexinV-Cy5 reagent
(BioVision) and 50mg of propidium iodide (PI) in 250mlo f
Annexin-V binding buffer (BioVision) for 5 min at room
temperature. As an internal FACS volume standard, 2610
4 of
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added. The beads are small, resulting in a high intensity in the
sideward scatter channel, and do not interfere with the cells to be
analyzed. Cells were analyzed by FACS until 5,000 beads were
counted and the numbers of the cells in the indicated gates were
recorded.
For analysis of the cell cycle status, the infected cells were
incubated with the thymidine analog BrdU for 2hrs prior to FACS
analysis at each time point. The cells were stained with an APC-
coupled BrdU-specific antibody after fixation and permeabiliza-
tion, and the cellular DNA was counter-stained with the DNA
intercalating dye 7-AAD according to the manufacturer’s protocol
(BrdU Flow Kit, BD Biosciences Pharmingen). 3610
4 cells were
acquired in FACS analysis. The FACS data were gated for cells in
the G0/G1,S ,G 2/M phases of the cell cycle and for cells with a
subG1 DNA content. The total of all events was set to 100%.
Absolute quantification of EBV-encoded microRNAs by
stem-loop real-time PCR
Total RNA was extracted from infected cells using the Trifast
reagent (peqGOLD). For cDNA synthesis, 500 ng of total RNA
was reverse-transcribed using Superscript III reverse transcriptase
(Invitrogen) with the mixture of miRNA specific stem-loop primers
shown in Supporting Table S2. In the quantitative reconstruction
experiments, total RNA from DmirALL EBV-infected LCLs was
used as an EBV miRNA-negative but complex RNA sample in
reverse transcription (RT) reactions. Details for reverse transcrip-
tion reaction were described previously [52]. 4ng of cDNA
aliquots from each sample were subjected to quantitative real-time
PCR analysis. Each 10ml PCR reaction contained 0.5mM forward
primer, 0.5mM reverse primer, and 16SYBR green mix (Roche).
The PCR reaction was performed in 96-well cluster plates at 95uC
for 10min, followed by 45 cycles of 95uC for 15sec, 60uC for 1min
with 10 initial cycles of touchdown steps (70–60uC). The absolute
copy number of each miRNA in the test samples was
reconstructed with the aid of standard curves generated with the
serial dilution of synthetic miRNA (Metabion) as reference. The
synthetic miRNAs were identical to the mature miRNA sequences
as annotated in the microRNA database (miRBase, release 14,
Sept. 2009; http://www.mirbase.org).
Supporting Information
Figure S1 Alignments and predicted structures of mutant
miRNAs. This multi-page figure shows alignments (pages 1 to 6)
and predicted secondary structure images (pages 7 to 13) of the 25
pre-miRNAs encoded by EBV field strains (represented by the
EBV GenBank entry AJ507799) and the corresponding sequences
in the mutant strains (DmirBHRF1, DmirALL, +mirBART) as
well as the prototypic parental 2089 EBV strain (wt), which is a
molecular clone of the EBV B95.8 genome. Secondary structures
were predicted using the Vienna RNAfold package [53] and are
indicated by bracket notation above and below the aligned
sequences. Regions that encode mature miRNA sequences or their
scrambled counterparts are shown in boldface on grey background
in the alignments, or in red in the structure images. The labelling
to the right of aligned sequences and underneath the structure
images denote whether the particular miRNA corresponds to the
AJ507799 sequence (shown at the top of each alignment and
structure image pair), or is mutated/deleted in the DmirBHRF1,
DmirALL, +mirBART or wt strains. Note that the parental,
prototypic 2089 (wt) strain and therefore all mutant strains inherit
the B95-8 deletion, which affects 16 of the 22 pre-miRNAs
encoded in the BART region of AJ507799 (indicated by dashes in
the alignments). The B95-8 deletion also truncates and fuses the
proximal 3/4ths of the pre-miR-BART5 region to sequences
located within the LF1 open reading frame (shown in italics in the
alignments on page 2 of the Supporting Figure S1). As shown in
the structure predictions for the wt / B95-8 strain (page 9, left
structure image in the lower panel), these fused pre-miRNA
sequences are unable to form a hairpin and therefore cannot
produce a mature miR-BART5 species, even though its coding
sequence is left intact. The coding region was nevertheless
scrambled in DmirBHRF1 as well as DmirALL (see bottom
alignment and right structure image on pages 2 and 9,
respectively). In contrast, in +mirBART the capacity to produce
miR-BART5 as well as the 16 deleted pre-miRNAs was restored
by insertion of an expression cassette (see main text for details).
The region encoding the mature ebv-miR-BART4* was not
scrambled in DmirBHRF1 or DmirALL because this miRNA had
not been discovered at the time of mutant design. However, the
mutation of the mature ebv-miR-BART4 sequences efficiently
destroys the pre-miRNA hairpin structure (see alignment on page
1 and structure prediction on page 8 of Supporting Figure S1) and
therefore also ablates expression of ebv-miR-BART4*.
Found at: doi:10.1371/journal.ppat.1001063.s001 (0.75 MB PDF)
Figure S2 Statistical cell cycle analysis of LCLs infected with
miRNA mutant EBVs. LCLs infected with the different miRNA
mutant EBVs were cultivated for up to five months and analyzed
for their cell cycle distributions as in Figure 4B. The fractions of
cells in S phase [%] from four independent experiments were
analyzed by the paired t test (two-tailed). The significance values
were calculated and shown above the boxes and whiskers (10 to
90% percentiles). Means (+) are indicated. LCLs infected with
DmiBHRF1 and DmirALL mutant EBVs showed a slight
reduction of cells in S phase when compared to prototype 2089
and +mirBART EBV-infected cells, which was mostly statistically
significant (p#0.05) suggesting a possible role of EBV’s BHRF1
miRNAs in controlling cell proliferation in established LCLs.
Found at: doi:10.1371/journal.ppat.1001063.s002 (0.03 MB PDF)
Figure S3 Quantitative RT-PCR analysis of BHRF1 mRNA
transcripts in prototype 2089 or DmirBHRF1 EBV-infected cells.
(A) Relative expression of BHRF1 mRNA levels in established
LCLs infected with the prototype 2089 (wt) or DmirBHRF1 EBV
compared to a reference LCL infected with a BZLF1 knockout
EBV (DZ) [41,51] that does not support lytic transcription of
BHRF1. cDNA synthesis was performed from total RNA after
DNase I treatment as described previously [41]. The quantitative
PCR reaction was performed with the following conditions:
95uC for 10 min for initial denaturation followed by 45 cycles at
95uC for 1sec, 60uC for 10sec, and 72uC for 7sec. Primer
sequences are listed in Supporting Table S3. The obtained
values were normalized to the cellular transcript of cytochrome c
as an internal reference and expressed relative to the normalized
value of the LCL line DZ, which served as a control and
reference. The arbitrary value of 1 was assigned to this LCL,
which had been established with a lytic-cycle deficient BZLF1-
knockout mutant EBV [51]. The error bars represent the
standard deviation of the means of cells from five different
donors. (B) Relative expression levels of the BHRF1 transcript in
primary B cells at day 5 p.i. infected with prototype 2089 or
DmirBHRF1 EBV. Primary human B cells isolated from
adenoids were infected at a concentration of 4.5610
5 per ml
with an MOI of 0.2. Data represent the means and standard
deviations of three independent experiments. Uninfected cells
are indicated (Cont).
Found at: doi:10.1371/journal.ppat.1001063.s003 (0.12 MB PDF)
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BART miRNAs in primary B cells infected with the prototype
2089 EBV or selected miRNA mutant EBVs. Primary human B
cells of three donors isolated from adenoids (4.5{mulitply} 10
5 per
ml) were infected with prototype 2089 (wt), DmirBHRF1 or +mir
BART EBVs as indicated with an MOI of 0.2. At day 5 p.i., cells
were harvested and two BHRF1 miRNAs, miR-BHRF1-1 (panel
A) and miR-BHRF1-2-3p (panel B) and four BART miRNAs,
miR-BART1-5p (panel C), miR-BART2-5p (panel D), miR-
BART8-5p (panel E), and miR-BART 22 (panel F) were
quantified by stem-loop PCR assays as described in Materials
and Methods. In primary cells early after infection miR-BHRF1-1
and miR-BHRF1-2-3p are expressed at about four- and twofold
higher levels, respectively, as compared to established LCLs
(Figure 2). Similarly, BART miRNAs are expressed higher in
freshly infected cells as compared to their established LCLs but the
extent varies. In case of miR-BART22 levels were increased about
ninefold, but miR-BART8-5p was only 1.5fold higher expressed
than in LCLs established with +mirBART EBV, for example
(compare Figure 2E and Supporting Figure S4E). JM LCL is a
spontaneous LCL infected with an uncharacterized field strain of
EBV encoding 44 viral miRNAs; DmirBHRF1 EBV served as a
negative control. Data were assessed and evaluated as in Figure 2.
Found at: doi:10.1371/journal.ppat.1001063.s004 (0.16 MB PDF)
Table S1 Primers used to amplify the galK targeting cassette.
Found at: doi:10.1371/journal.ppat.1001063.s005 (0.05 MB
DOC)
Table S2 DNA oligonucleotides for quantitative stem-loop PCR
assays.
Found at: doi:10.1371/journal.ppat.1001063.s006 (0.06 MB
DOC)
Table S3 PCR primer pairs for detection of cDNAs.
Found at: doi:10.1371/journal.ppat.1001063.s007 (0.04 MB
DOC)
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